What Should Be Characterized in Antibody-Drug Conjugates? Key Attributes, Analytical Methods, and Data Interpretation

Inquiry

Why Antibody-Drug Conjugates Require Multi-Attribute Characterization?

An antibody-drug conjugate (ADC) combines an antibody, a linker, and a payload in one heterogeneous molecular system. Characterization therefore needs to answer more than whether conjugation occurred. Development teams need to know how much payload is attached, where it is attached, whether unwanted molecular populations are present, whether the conjugate remains structurally stable, and whether the expected molecular functions are retained.

The most useful ADC data are interpreted as connected measurements. For example, a change in average DAR becomes more informative when it is viewed together with drug-load distribution, free payload, aggregation, and conjugation-site data. Likewise, a change in functional potency may be easier to explain when binding, internalization, payload release, and structural stability are analyzed together.

Table.1 Core Questions in ADC Characterization.

Attribute Group	What Needs to Be Measured?	Main Analytical Readouts	Why It Matters?
Molecular composition and conjugation	Antibody identity, DAR, drug-load distribution, conjugation sites, linker-payload integrity	Mass, sequence coverage, DAR values, individual DAR populations, site occupancy	Confirms what molecular species were produced and how payload is attached.
Purity and heterogeneity	Unconjugated antibody, free payload, aggregates, fragments, charge and glycan variants	Relative peak areas, impurity content, HMW/LMW species, acidic/basic populations	Reveals unwanted molecular populations that may not be visible from average DAR alone.
Structural stability and biophysical behavior	Conformation, thermal stability, colloidal behavior, deconjugation, time-dependent changes	Spectral profiles, T_m, particle size, DAR retention, aggregate formation	Shows whether conjugation changes protein behavior or whether the ADC changes over time.
Functional attributes	Binding, internalization, payload release, functional potency, Fc-related activity	K_D, uptake kinetics, released species, IC₅₀/EC₅₀, functional response	Connects molecular characterization with the behavior of the complete ADC.

How to use the reference ranges below: the values and patterns in this article are development references, not universal pass/fail limits. ADC architecture, conjugation chemistry, linker hydrophobicity, payload properties, formulation, concentration, and analytical conditions can all shift the expected result. The most informative comparison is often the designed target, the corresponding unconjugated antibody, or the same ADC measured at an earlier time point.

Molecular Composition and Conjugation Attributes in ADCs

This group establishes the molecular identity of the ADC and defines how the linker-payload is distributed across the antibody population. Intact-, subunit-, and peptide-level measurements should complement rather than replace one another.

Antibody Identity and Primary Structure

Why measure: Conjugation does not eliminate the need to confirm that the expected antibody backbone is present. An intact mass result alone may confirm overall composition but cannot localize an unexpected sequence-level change.
What to measure: Intact and subunit molecular mass, amino-acid sequence coverage, expected terminal processing, and unexpected peptide-level mass shifts.
Methods and instruments: Intact or subunit LC-HRMS followed by peptide mapping and LC-MS/MS testing. Reduced mass analysis can simplify heavy- and light-chain interpretation when intact spectra are highly heterogeneous.
How to interpret: The observed antibody backbone should match the theoretical sequence after accounting for expected glycans and conjugated linker-payload mass. Unassigned mass differences or missing peptide regions should be investigated before they are attributed to conjugation.

Disulfide Bond Integrity

Why measure: Disulfide connectivity supports antibody architecture, while cysteine-based ADC strategies may intentionally disrupt selected interchain disulfides to create conjugation sites.
What to measure: Expected disulfide-linked peptides, unintended disulfide pairings, free cysteine or free-thiol populations, and chain association under non-reducing conditions.
Methods and instruments: Non-reduced peptide mapping with LC-MS/MS, reduced versus non-reduced CE-SDS, and free-thiol analysis when additional information is needed.
How to interpret: A changed disulfide profile is not automatically abnormal in a cysteine-conjugated ADC. The key question is whether the observed connectivity matches the intended conjugation design. Unexpected scrambled disulfides or excessive unpaired thiols point to unintended reduction, reoxidation, or structural rearrangement.

Drug-to-Antibody Ratio (DAR) and Drug-Load Distribution

Why measure: Average DAR defines mean payload loading, while drug-load distribution reveals the individual populations that create that average. The same average DAR can result from very different molecular distributions.
What to measure: Average DAR, relative abundance of DAR0 and loaded species, width of the distribution, and the presence of high-DAR or low-DAR tails.
Methods and instruments: HIC is highly informative when drug-loaded populations are sufficiently resolved; intact or subunit LC-MS assigns populations by molecular mass. UV-Vis testing can provide a rapid average DAR estimate when antibody and payload absorbance can be separated mathematically.
How to interpret: Many ADC architectures operate within an average DAR of roughly 2-8, but the intended target is design-specific. An unchanged average DAR does not prove an unchanged sample if DAR0 and high-DAR species increase simultaneously. Distribution should therefore be reviewed together with the average.

Conjugation Site and Site Occupancy

Why measure: Payload location influences molecular homogeneity and can affect binding, structural behavior, and linker accessibility even when average DAR remains unchanged.
What to measure: Modified peptide identity, exact or localized attachment sites, percentage occupancy at intended sites, distribution across alternative sites, and unexpected off-target conjugation.
Methods and instruments: Enzymatic peptide mapping followed by high-resolution LC-MS/MS. Fragment-ion data are used to localize modification within individual peptides.
How to interpret: Site-specific ADCs should show a concentrated occupancy pattern around designed sites, while stochastic lysine or cysteine conjugation is expected to produce broader positional heterogeneity. Increasing off-target occupancy can explain sample-to-sample differences that are invisible in average DAR.

Linker-Payload Integrity

Why measure: An ADC can retain the expected antibody mass profile while still developing chemically altered linker-payload species. Linker changes can also precede a detectable decrease in total payload loading.
What to measure: Intact linker-payload attachment, characteristic linker-related mass changes, cleavage products, hydrolysis products, modified payload species, and loss of linker-payload from the antibody.
Methods and instruments: Intact, subunit, and peptide-level LC-MS together with HRMS testing for accurate mass assignment. RP-LC-MS is useful when small linker-payload related species also need to be detected.
How to interpret: The intact conjugated form should dominate the expected molecular population. New mass losses, cleavage products, or related small-molecule peaks can indicate linker transformation, payload loss, or sample-handling-induced degradation.

Table.2 Reference Patterns for Molecular Composition and Conjugation Attributes.

Attribute	Typical / Reference Pattern	Abnormal Signal	Possible Direction to Investigate
Antibody identity and primary structure	ADC mass is consistent with the antibody backbone plus expected linker-payload additions; near-complete sequence coverage is preferred.	Unassigned intact/subunit mass, missing peptides, unexpected peptide mass shifts.	Sequence variant, truncation, chemical modification, unexpected conjugation, or sample-processing artifact.
Disulfide bond integrity	Expected disulfide connectivity dominates; intended cysteine utilization agrees with the conjugation design.	Unexpected disulfide pairs, excessive free thiols, altered chain pattern.	Over-reduction, disulfide scrambling, incomplete reoxidation, or structural stress.
Average DAR	Common ADC designs span approximately DAR 2-8; the correct value is the project-specific target rather than a universal optimum.	Average DAR moves below or above the designed range.	Conjugation efficiency, reagent ratio, purification bias, payload loss, or enrichment of high-DAR species.
Drug-load distribution	Cysteine-based stochastic ADCs may contain DAR0/2/4/6/8 populations; site-specific ADCs generally show a narrower distribution.	Increasing DAR0, broader distribution, or expanding high-DAR tail.	Uneven conjugation, incomplete reaction, over-conjugation, deconjugation, or sample instability.
Conjugation site and occupancy	Designed sites dominate for site-specific ADCs; stochastic ADCs show a chemistry-dependent distribution.	New sites, reduced occupancy at intended sites, increasing positional heterogeneity.	Reaction selectivity, site accessibility, antibody structural change, or incomplete conjugation.
Linker-payload integrity	Intact linker-payload species dominate and cleavage-related species remain low.	New mass-loss species, cleavage products, or increasing released payload-related peaks.	Linker instability, hydrolysis, exchange reaction, oxidation, or handling-induced change.

Purity and Heterogeneity Attributes in ADCs

Purity analysis asks a different question from molecular identity: what other molecular populations are present in the sample? ADC heterogeneity can arise from incomplete conjugation, residual small molecules, protein association, fragmentation, antibody modifications, or variation already present in the starting antibody.

Unconjugated Antibody and Under-Conjugated Species

Why measure: Average DAR can hide a substantial low-load population. Directly measuring DAR0 and low-DAR species shows whether the conjugation process produced the desired population distribution.
What to measure: Relative abundance of DAR0, DAR1/DAR2 or other low-load species appropriate to the chemistry, together with their change across preparations or time points.
Methods and instruments: HIC for hydrophobicity-resolved populations, intact/subunit LC-MS for mass-resolved populations, and selected charge-based separations when conjugation strongly changes surface charge.
How to interpret: A rising DAR0 or low-DAR fraction may indicate incomplete conjugation, inefficient removal of unconjugated antibody, or later payload loss. Interpretation should always be checked against average DAR.

Free Payload and Linker-Related Species

Why measure: Small-molecule payload or linker-payload species may remain after conjugation and purification, or they may appear later if the ADC loses payload.
What to measure: Free payload concentration, unconjugated linker-payload, hydrolyzed or cleaved linker-related species, and time-dependent increases in these components.
Methods and instruments: RP-HPLC or UPLC with suitable detection, LC-MS/MS for sensitive quantitative analysis, and HRMS when confirmation of an unknown related species is needed.
How to interpret: Free payload should normally remain low after effective purification. A rising free-payload signal during storage or stress is more informative when accompanied by decreasing DAR or increasing low-DAR species.

Aggregates and Fragments

Why measure: Conjugation can increase surface hydrophobicity or disrupt local structure, creating a greater tendency toward self-association or fragmentation.
What to measure: Monomer percentage, high-molecular-weight species, dimers and larger soluble aggregates, low-molecular-weight species, and chain-level fragments.
Methods and instruments: SEC-UV or SEC-MALS for soluble size variants and CE-SDS under reducing and non-reducing conditions for chain-level fragmentation. The two methods provide complementary rather than identical views.
How to interpret: A monomer-dominant SEC profile with low aggregate and fragment levels is generally preferred. Increasing HMW species points toward association or aggregation; increasing LMW species points toward cleavage or fragmentation. CE-SDS can detect fragments that remain associated under native SEC conditions.

Charge Variants

Why measure: ADC charge heterogeneity can originate from antibody modifications as well as conjugation itself. Charge profiles may therefore reveal molecular differences not resolved by size or DAR analysis.
What to measure: Main, acidic, and basic populations; apparent pI distribution; new peaks introduced after conjugation; and time-dependent movement between charge populations.
Methods and instruments: Ion exchange chromatography (IEX), iCIEF, and LC-MS peptide mapping when root-cause identification is needed.
How to interpret: A new acidic or basic population should not automatically be assigned to one modification. DAR, conjugation site, deamidation, oxidation, terminal processing, and other molecular changes can all influence the profile.

Glycan Heterogeneity

Why measure: The antibody component naturally contains multiple glycoforms, and glycan distribution can contribute to molecular and functional heterogeneity.
What to measure: Major glycan classes, relative glycoform abundance, glycopeptide distribution at the Fc glycosylation site, and differences between the parent antibody and the ADC.
Methods and instruments: Released-glycan profiling by HILIC with fluorescence or MS detection, glycopeptide LC-MS/MS, and intact/subunit MS for higher-level glycoform information.
How to interpret: There is no universal glycan percentage for all ADCs. The most useful comparison is with the corresponding antibody or an established project reference. A major shift may reflect antibody-source variation, processing history, or selective behavior during conjugation and purification.

Table.3 Reference Patterns for ADC Purity and Heterogeneity.

Attribute	Typical / Reference Pattern	Abnormal Signal	Possible Direction to Investigate
Unconjugated and low-DAR species	Minor populations relative to the intended dominant drug-load species; exact percentage depends on conjugation design.	Increasing DAR0 or low-DAR fraction.	Incomplete conjugation, insufficient separation, or payload loss.
Free payload and linker-related species	Low or near the analytical method's quantitative limit after effective purification; stable over time.	Elevated initial level or increasing concentration.	Residual conjugation reagent, incomplete purification, linker cleavage, or deconjugation.
Aggregates	Monomer should dominate; well-behaved preparations generally show low aggregate levels, often in the low-single-digit percentage range or below.	Growing dimer/HMW peak or rapid increase under stress.	Hydrophobicity, self-association, structural destabilization, or formulation-dependent aggregation.
Fragments	Low relative LMW signal and stable chain profile.	New LMW SEC peaks or additional CE-SDS bands.	Backbone cleavage, hinge-region instability, linker-related structural stress, or sample handling.
Charge variants	Reproducible main/acidic/basic distribution consistent with the ADC architecture and reference sample.	New peaks, expanding acidic/basic populations, or a progressive profile shift.	Protein modification, conjugation heterogeneity, fragmentation, or site-specific chemical change.
Glycan profile	Major glycoform pattern broadly consistent with the corresponding antibody unless the ADC design intentionally modifies glycans.	Unexpected gain or loss of major glycoforms.	Starting-antibody variation, glycan-directed conjugation effect, processing difference, or selective recovery.

Structural Stability and Biophysical Attributes in ADCs

Payload attachment can change surface hydrophobicity, local flexibility, intermolecular interactions, and thermal behavior. This section therefore focuses on whether the ADC remains conformationally intact, dispersed in solution, and chemically conjugated over time.

Higher-Order Structure and Conformational Integrity

Why measure: Mass-based measurements confirm composition but do not fully describe three-dimensional protein structure. Conjugation can introduce local or global conformational changes without a large change in molecular mass.
What to measure: Secondary-structure signature, tertiary aromatic environment, overall spectral profile, and differences between parent antibody, freshly prepared ADC, and aged or stressed ADC.
Methods and instruments: CD spectroscopy testing for far- and near-UV structural profiles, supplemented by fluorescence, FTIR, or other biophysical techniques when more information is required.
How to interpret: Closely overlapping profiles generally support preserved global structure. A reproducible spectral shift should be interpreted together with aggregation, thermal stability, and binding data before the molecular consequence is assigned.

Thermal Stability

Why measure: Conjugation may alter the stability of individual antibody domains even when the ADC remains monomeric under routine conditions.
What to measure: Melting temperature T_m, thermal transition onset, number and shape of thermal transitions, aggregation onset where applicable, and changes relative to the parent antibody or time-zero sample.
Methods and instruments: DSC, differential scanning fluorimetry, temperature-dependent spectroscopy, and thermal analysis combined with light scattering when unfolding and aggregation need to be differentiated.
How to interpret: The direction and magnitude of ΔT_m versus a matched reference is usually more informative than an absolute T_m value. Lower transitions, broader peaks, or earlier aggregation can indicate reduced structural stability.

Colloidal Stability and Particle Formation

Why measure: Hydrophobic linker-payload groups can increase intermolecular association even when SEC still shows a predominantly monomeric sample.
What to measure: Hydrodynamic diameter, size distribution, polydispersity, appearance of larger scattering populations, and change in size with concentration or storage.
Methods and instruments: DLS testing for rapid solution-state sizing, complemented by SEC, MALS, NTA, or other particle-analysis techniques when larger or lower-abundance populations require confirmation.
How to interpret: Monomeric IgG commonly gives a hydrodynamic diameter of roughly 9-12 nm under dilute conditions. ADC values are condition- and architecture-dependent, but a large upward shift, broad multimodal distribution, or new high-size population suggests self-association or particle formation and should be confirmed orthogonally.

Deconjugation and Payload Loss

Why measure: A chemically intact antibody can gradually lose linker-payload, changing the functional ADC population without necessarily producing obvious protein fragmentation.
What to measure: DAR retention, redistribution toward lower-DAR species, increase in DAR0, free payload, linker-related products, and site-specific loss where measurable.
Methods and instruments: HIC and intact/subunit LC-MS for DAR changes, peptide mapping for site-level information, and LC-MS/MS for released small-molecule payload or linker-related species.
How to interpret: A decrease in average DAR is strongest evidence of deconjugation when it is accompanied by growth of lower-DAR species and increasing released payload. A DAR shift without released species may require investigation of method response, sample recovery, or population redistribution.

Chemical and Structural Changes during Storage

Why measure: Storage-related change can occur through more than one pathway. Monitoring only DAR or only aggregation can miss other important molecular changes.
What to measure: DAR and drug-load distribution, free payload, aggregate and fragment levels, charge profile, peptide-level modifications, higher-order structure, and selected functional readouts across time points.
Methods and instruments: A coordinated panel using HIC, LC-MS, SEC, IEX/iCIEF, CE-SDS, peptide mapping, spectroscopy, and biophysical measurements.
How to interpret: Look for correlated trends rather than isolated changes. DAR decrease plus free-payload increase points toward payload loss; HMW increase with stable DAR points more strongly toward protein association; charge changes with stable size and DAR suggest a different chemical pathway.

Table.4 Reference Patterns for ADC Structural and Biophysical Stability.

Attribute	Typical / Reference Pattern	Abnormal Signal	Possible Direction to Investigate
Higher-order structure	ADC spectral profile remains broadly comparable with the matched antibody or initial ADC reference.	Reproducible spectral shift, loss of characteristic features, increased baseline/scattering.	Conformational change, unfolding, aggregation, or formulation effect.
Thermal stability	No universal ADC T_m; stable constructs show reproducible transitions with limited shift from the relevant reference.	Lower T_m, broader transition, disappearance of a transition, or earlier aggregation onset.	Domain destabilization, conjugation-site effect, hydrophobic payload effect, or structural heterogeneity.
Hydrodynamic size	Monomeric IgG is commonly about 9-12 nm in hydrodynamic diameter under dilute conditions; ADCs should be interpreted relative to formulation and reference.	Large diameter increase, broad distribution, or additional high-size modes.	Reversible self-association, soluble aggregate formation, or larger particle generation.
Payload retention	Average DAR and distribution remain stable while released payload stays low.	DAR decreases while lower-DAR species or free payload increase.	Deconjugation, linker cleavage, exchange chemistry, or payload loss.
Storage profile	Small, explainable changes relative to time-zero across composition, purity, structure, and function.	Parallel changes across multiple attributes or rapid movement in one sensitive marker.	Identify whether the dominant pathway is aggregation, fragmentation, chemical modification, or linker-payload instability.

Functional Attributes of Antibody-Drug Conjugates

Functional testing determines whether the structurally characterized ADC still performs the molecular steps expected from its design. Binding, internalization, payload release, and downstream activity should be viewed as a sequence: a change at an upstream step can explain a change observed later.

Antigen-Binding Affinity and Specificity

Why measure: Conjugation close to a binding region, excessive loading, aggregation, or structural change can alter target recognition even when the antibody sequence itself is unchanged.
What to measure: Equilibrium binding affinity K_D, association rate k_on, dissociation rate k_off, concentration-dependent binding, and target-selective versus non-target binding.
Methods and instruments: SPR, BLI, flow-cytometric binding assays, and suitable plate-based binding assays. Kinetic methods are useful when an apparently unchanged endpoint signal hides altered association or dissociation behavior.
How to interpret: Many ADC antibody components show sub-nanomolar to low-nanomolar binding, but the correct comparison is the corresponding parent antibody. A meaningful affinity loss should be checked against conjugation site, aggregation, and higher-order structure before the cause is assigned.

Cellular Internalization

Why measure: Strong surface binding does not guarantee efficient cellular uptake. Internalization can become the limiting step between target recognition and payload delivery.
What to measure: Percentage internalized, uptake rate, time to intracellular accumulation, localization to relevant intracellular compartments, and comparison between ADC and unconjugated antibody.
Methods and instruments: Fluorescence-based cell assays, flow cytometry, imaging, microscopy, labeled-ADC uptake assays, or quantitative internalization assays matched to the target system.
How to interpret: There is no universal percentage that defines adequate internalization. The useful result is a reproducible time-dependent uptake profile. Similar binding but weaker internalization suggests that the functional bottleneck occurs after target engagement rather than at the binding step.

Payload Release

Why measure: The ADC may bind and internalize correctly but still fail to generate the intended released payload species if linker processing is inefficient or follows an alternative pathway.
What to measure: Released payload identity, release rate, linker-containing intermediates, disappearance of intact conjugated species, and the time-dependent relationship between precursor and released products.
Methods and instruments: LC-MS/MS, HRMS, chromatographic time-course analysis, and appropriate biochemical release systems designed around the linker chemistry.
How to interpret: A useful profile shows formation of the expected released species with a time course that matches the intended linker mechanism. Accumulation of unexpected intermediates or premature release suggests an alternative cleavage pathway or insufficient linker stability.

Functional Potency

Why measure: Functional potency integrates several upstream properties: target binding, internalization, payload release, drug loading, and the activity of the released payload.
What to measure: Concentration-response curve, IC₅₀ or EC₅₀, maximal response, curve slope, target-dependent activity, and comparison among ADC samples with different analytical profiles.
Methods and instruments: Cell proliferation and activity testing or another mechanism-appropriate cell-based functional assay.
How to interpret: Many potent ADC systems can produce responses in the picomolar-to-nanomolar concentration range in sensitive target-positive models, but absolute potency is highly target-, payload-, and assay-dependent. A potency shift should be traced upstream through binding, internalization, DAR, payload release, and aggregation data.

Fc-Mediated Effector Functions

Why measure: Fc-related functions may be relevant when the antibody component is designed to retain them. They are not equally important for every ADC architecture and should therefore be selected according to project design.
What to measure: Fc-receptor binding, Fc-dependent cellular responses, and the relationship between Fc activity, glycan profile, aggregation, and higher-order structure.
Methods and instruments: Fc-receptor binding assays, SPR or BLI where appropriate, and mechanism-relevant cell-based functional assays.
How to interpret: If Fc function is intended to be retained, the ADC should remain broadly comparable with the corresponding antibody. A shift should be evaluated alongside glycan heterogeneity, conformation, and aggregation rather than being attributed directly to payload attachment.

Table.5 Reference Patterns for Functional ADC Attributes.

Functional Attribute	Typical / Reference Pattern	Abnormal Signal	Possible Direction to Investigate
Antigen-binding affinity	Often sub-nanomolar to low-nanomolar for high-affinity ADC antibodies; retention relative to parent antibody is more important than one absolute K_D.	Large K_D increase, faster dissociation, or lower maximum binding response.	Conjugation near binding region, conformational change, aggregation, or assay interference.
Binding specificity	Strong target-dependent binding with low non-target signal in the selected assay system.	Increasing non-target interaction or reduced target-to-background separation.	Aggregation, altered surface properties, nonspecific hydrophobic interaction, or assay design.
Cellular internalization	Project-specific; should show reproducible time-dependent uptake and expected intracellular localization.	Surface binding is retained but uptake is slow, incomplete, or poorly localized.	Target trafficking, conjugation effect, DAR-related physicochemical change, or altered receptor interaction.
Payload release	Expected released species increases in a design-consistent time course while intact precursor decreases.	Premature release, very slow release, or accumulation of unexpected intermediates.	Linker instability, inefficient cleavage, alternative catabolic pathway, or sample-condition mismatch.
Functional potency	Highly system-dependent; potent ADC responses are frequently observed from pM to nM ranges in sensitive target-positive cell models.	Right-shifted concentration-response curve or reduced maximal response.	Lower DAR, weaker binding, poor internalization, inefficient release, aggregation, or reduced payload activity.
Fc-mediated function	Comparable with parent antibody when Fc function is intended to be retained.	Reduced receptor binding or functional response.	Glycan shift, conformational change, aggregation, or conjugation-related steric effects.

Need to Connect ADC Analytical Results with Their Molecular Meaning?

From DAR and conjugation-site mapping to aggregation, structural stability, and functional testing, BOC Sciences can build an integrated characterization workflow around your ADC architecture and analytical questions.

Talk to an Expert

BOC Sciences Solutions for Antibody-Drug Conjugate Characterization

ADC characterization is most effective when the analytical plan begins with the molecular question rather than with a fixed list of instruments. BOC Sciences supports ADC projects with complementary chromatographic, mass spectrometric, spectroscopic, biophysical, and functional approaches that can be combined according to conjugation chemistry, expected DAR range, payload properties, sample availability, and the type of information required. Instead of relying on one analytical readout, our scientists can build an integrated data set that connects ADC composition, purity, structural behavior, and function.

Integrated Physicochemical Characterization of ADCs

Physicochemical characterization can cover the intact ADC, antibody subunits, peptides, and small-molecule components within one coordinated analytical program. Depending on the project, the workflow may include molecular-mass confirmation, peptide mapping, disulfide assessment, drug-loading analysis, conjugation-site identification, size and charge profiling, free-payload analysis, and biophysical characterization. This multi-level approach is particularly useful when one observation requires explanation by another technique. For example, an unexpected chromatographic peak can be investigated by mass spectrometry, while a structural difference can be compared with binding or other functional results.

DAR, Drug Distribution, and Conjugation-Site Analysis

DAR analysis can be designed around both the average value and the distribution that produces it. HIC, UV-Vis measurements, intact or subunit MS, and peptide-level analysis provide complementary information, and the most appropriate combination depends on the conjugation architecture. When site-specific information is needed, peptide mapping and tandem mass spectrometry can localize linker-payload attachment and evaluate site occupancy. The final interpretation can therefore move beyond a single DAR number to describe how payload molecules are distributed across ADC molecules and attachment sites.

ADC Purity, Aggregation, and Variant Analysis

Purity assessment can include unconjugated antibody, under-conjugated populations, free payload, soluble aggregates, fragments, charge variants, and other conjugate-related species. Because these components differ in size, hydrophobicity, charge, and molecular mass, BOC Sciences can combine orthogonal separation techniques rather than forcing all forms into a single analytical method. Cross-comparison of SEC, HIC, IEX, electrophoretic, and MS data can help distinguish genuine ADC heterogeneity from method-dependent separation behavior and provide a clearer explanation of the observed sample profile.

Customized Analytical Workflows and Data Interpretation

Different ADC architectures create different analytical challenges. A highly hydrophobic payload may complicate recovery and chromatographic behavior; random conjugation can produce a broad population of positional isomers; a site-directed construct may require more detailed occupancy analysis; and a linker designed for controlled cleavage may require careful sample handling to avoid generating changes during analysis. BOC Sciences can adapt sample preparation, separation conditions, detection platforms, and orthogonal confirmation to these specific questions.

Data interpretation is built around relationships among attributes. DAR is read together with drug-load distribution, site occupancy, and free payload. Aggregation data are compared with colloidal and higher-order structural measurements. Charge profiles are interpreted in the context of conjugation chemistry rather than assumed to represent conventional antibody charge variants. Functional differences are compared with binding, internalization, structural, and payload-related data. This connected approach helps transform a large analytical data set into a practical molecular explanation of how an ADC sample is composed and how it behaves.

Table.6 ADC Characterization Related Services at BOC Sciences.

Service Name	Description	Inquiry
Antibody Conjugation	Customized antibody conjugation support for developing and studying antibody-linker-payload systems with project-specific conjugation strategies.	Inquiry
Structure Characterization	Integrated structural analysis supporting molecular identity, primary-structure assessment, structural integrity, and complementary characterization of complex conjugates.	Inquiry
LC-MS Testing	LC-MS analysis for molecular-mass characterization, linker-payload related species, released payloads, and other ADC-associated molecular components.	Inquiry
HIC Chromatography Services	Hydrophobic interaction chromatography for resolving ADC populations according to hydrophobicity and supporting DAR and drug-load distribution analysis.	Inquiry
SEC/GPC Testing	Size-based characterization of monomeric ADCs, soluble high-molecular-weight populations, and selected low-molecular-weight species.	Inquiry
Cell-Based Assay Services	Customized cell-based analytical approaches for studying ADC-related cellular responses, internalization-dependent behavior, and functional activity.	Inquiry

Ready to Build a Complete Characterization Profile for Your ADC?

Connect with BOC Sciences to discuss your antibody, linker, payload, conjugation strategy, and analytical questions. Our team can design a focused workflow that connects key ADC attributes with the methods and data interpretation needed to understand your conjugate.